Giving HIV injections at home with a helper
Part of Immune system & allergy, Infections clinical trials.
This study tests whether having a trained friend or family member give you your HIV injections at home is safe and works as well as getting them at a clinic. You may qualify if you are already on the injectable HIV medication cabotegravir/rilpivirine (Cabenuva) and have a support person willing to help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have already received the first two shots (loading dose) of the injectable HIV medication cabotegravir/rilpivirine (Cabenuva) without serious side effects.
- Your HIV is well controlled (viral load under 50 copies per mL).
- You have a family member, friend, or partner who can give you the injections at home.
- You have no known resistance to cabotegravir or rilpivirine, and your HIV treatment has never failed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study tests if a program that encourages positive activities (behavioral activation) can help people with HIV or on PrEP who also use substances improve their health. It focuses on those receiving long-acting injectable medications for HIV prevention or treatment.
This study tests a new shot (called VH4011499) that may help control HIV. It is given together with another shot, cabotegravir, so you might not need to take daily pills. The study is for people who have never treated their HIV before.
This study tests whether a pharmacist can safely give long-acting HIV medications every 4 or 8 weeks. It aims to help more people with HIV get this treatment easily.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.